STOCK TITAN

Alamar Biosciences (ALMR) COO receives RSUs, major option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Alamar Biosciences Chief Operating Officer Shiping Chen reported equity compensation grants and pre‑IPO share conversions, with no open‑market buying or selling. Chen received 37,220 shares of Common Stock as restricted stock units that vest monthly, bringing direct Common Stock holdings to 760,105 shares after the award.

The filing also shows automatic conversions of Class A Common Stock, Founders Preferred Stock, Series A‑1 Preferred Stock and Class B Common Stock into Common Stock immediately before Alamar’s IPO, plus administrative reclassifications of related stock options. Chen was granted a new stock option over 163,358 shares at $17.00 per share, alongside existing options with lower exercise prices.

Positive

  • None.

Negative

  • None.
Insider Chen Shiping
Role Chief Operating Officer
Type Security Shares Price Value
Conversion Class A Common Stock 247,311 $0.00 --
Conversion Founders Preferred Stock 73,200 $0.00 --
Conversion Series A-1 Preferred Stock 176,160 $0.00 --
Other Stock Option (Right to Buy) 300,883 $0.00 --
Other Stock Option (Right to Buy) 300,883 $0.00 --
Other Stock Option (Right to Buy) 12,190 $0.00 --
Other Stock Option (Right to Buy) 12,190 $0.00 --
Conversion Class B Common Stock 320,511 $0.00 --
Conversion Class B Common Stock 72,853 $0.00 --
Other Class B Common Stock 722,885 $0.00 --
Other Common Stock 722,885 $0.00 --
Grant/Award Common Stock 37,220 $0.00 --
Grant/Award Stock Option (Right to Buy) 163,358 $0.00 --
Holdings After Transaction: Class A Common Stock — 0 shares (Direct, null); Founders Preferred Stock — 0 shares (Direct, null); Series A-1 Preferred Stock — 0 shares (Direct, null); Stock Option (Right to Buy) — 0 shares (Direct, null); Class B Common Stock — 650,032 shares (Direct, null); Common Stock — 722,885 shares (Direct, null)
Footnotes (1)
  1. The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO"). The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO. Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
RSU grant 37,220 shares Common Stock RSUs vesting monthly from April 20, 2026
Common Stock holdings 760,105 shares Direct Common Stock owned after RSU grant
New option grant 163,358 shares at $17.00 Stock option expiring April 15, 2036
Existing option 300,883 shares at $3.34 Stock option expiring January 15, 2035
Existing option 12,190 shares at $7.60 Stock option expiring January 14, 2036
Converted Series A-1 Preferred 176,160 shares Converted into 72,853 Class B Common shares before IPO
Converted Founders Preferred 73,200 shares Converted into 73,200 Class B Common shares before IPO
Converted Class A Common 247,311 shares Converted into 247,311 Class B Common shares before IPO
restricted stock units ("RSUs") financial
"Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Class B Common Stock financial
"Each share of Class B Common Stock was reclassified into one share"
A class B common stock is one of multiple types of a company’s ordinary shares that carries specific rights—often different voting power or dividend priority—compared with other classes. For investors it matters because those differences affect how much influence you have over company decisions, the income you might receive, and how freely the shares trade; think of it like owning a car with different keys: some keys let you start the engine and open the trunk, others only unlock the door.
Series A-1 Preferred Stock financial
"The Series A-1 Preferred Stock is convertible into shares of Class B"
Series A-1 preferred stock is a specific class of company shares created in an early financing round that typically gives its holders priority over common shareholders for dividends and money if the company is sold or liquidates. Think of it as a special ticket with upfront privileges — often convertible into ordinary shares and sometimes carrying voting or protective rights — so investors use it to reduce risk and preserve control compared with ordinary stock.
Founders Preferred Stock financial
"The Class A Common Stock and Founders Preferred Stock automatically converted"
initial public offering financial
"immediately prior to the completion of the initial public offering of the Issuer's Common Stock"
An initial public offering (IPO) is when a private company first sells its shares to the public and becomes a stock-listed company. It matters because it allows the company to raise money from a wide range of investors, helping it grow, while giving early shareholders a way to sell some of their ownership.
stock option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise price of 17.0000"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chen Shiping

(Last)(First)(Middle)
C/O ALAMAR BIOSCIENCES, INC.
47071 BAYSIDE PARKWAY

(Street)
FREMONT CALIFORNIA 94538

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Alamar Biosciences, Inc. [ ALMR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class B Common Stock04/20/2026C(1)320,511A(1)650,032D
Class B Common Stock04/20/2026C(2)72,853A(2)722,885D
Class B Common Stock04/20/2026J(3)722,885D(3)0D
Common Stock04/20/2026J(3)722,885A$0722,885D
Common Stock04/20/2026A(4)37,220A$0760,105D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1704/16/2026A163,358 (5)04/15/2036Common Stock163,358$0163,358D
Class A Common Stock(1)04/20/2026C247,311 (1) (1)Class B Common Stock247,311$00D
Founders Preferred Stock(1)04/20/2026C73,200 (1) (1)Class B Common Stock73,200$00D
Series A-1 Preferred Stock(2)04/20/2026C176,160 (2) (2)Class B Common Stock72,853$00D
Stock Option (Right to Buy)$3.3404/20/2026J(3)300,883 (6)01/15/2035Class B Common Stock300,883$00D
Stock Option (Right to Buy)$3.3404/20/2026J(3)300,883 (6)01/15/2035Common Stock300,883$0300,883D
Stock Option (Right to Buy)$7.604/20/2026J(3)12,190 (7)01/14/2036Class B Common Stock12,190$00D
Stock Option (Right to Buy)$7.604/20/2026J(3)12,190 (7)01/14/2036Common Stock12,190$012,190D
Explanation of Responses:
1. The Class A Common Stock and Founders Preferred Stock are convertible into shares of Class B Common Stock on a 1:1 basis and have no expiration date. The Class A Common Stock and Founders Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock (the "IPO").
2. The Series A-1 Preferred Stock is convertible into shares of Class B Common Stock on a 1:2.418 basis and has no expiration date. The Series A-1 Preferred Stock automatically converted into shares of Class B Common Stock immediately prior to the completion of the IPO.
3. Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
4. Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
5. Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
6. The shares subject to the option vest in equal monthly installments over 48 months measured from January 16, 2025, subject to the reporting person's continuous service as of each such vesting date.
7. The shares subject to the option vest in equal monthly installments over 48 months measured from January 1, 2026, subject to the reporting person's continuous service as of each such vesting date.
/s/ Timothy White, Attorney-in-Fact04/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Alamar Biosciences (ALMR) COO Shiping Chen report in this Form 4?

Shiping Chen reported equity compensation and share conversions, not market trades. The filing includes a 37,220-share restricted stock unit grant and a 163,358-share stock option grant, plus automatic conversions of various preferred and Class B shares into Common Stock ahead of Alamar’s IPO.

How many Alamar Biosciences (ALMR) common shares does the COO hold after these transactions?

After the reported transactions, Shiping Chen directly holds 760,105 shares of Alamar Biosciences Common Stock. This figure reflects the new restricted stock unit grant and the reclassification of Class B Common Stock into Common Stock immediately prior to the company’s initial public offering.

What restricted stock units were granted to Alamar Biosciences (ALMR) COO Shiping Chen?

Chen received 37,220 shares of Common Stock in the form of restricted stock units. These RSUs vest monthly from the grant date, contingent on Chen’s continuous service with Alamar Biosciences at each vesting date, aligning compensation with ongoing employment over time.

What new stock option did the Alamar Biosciences (ALMR) COO receive?

Chen was granted a stock option for 163,358 shares of Common Stock at an exercise price of $17.00 per share. Twenty-five percent of these shares vest on April 16, 2027, with the remainder vesting monthly thereafter, subject to continued service, and expiring in 2036.

How were Alamar Biosciences (ALMR) preferred and Class B shares treated before the IPO?

Immediately before the IPO, Class A Common Stock and Founders Preferred Stock converted into Class B Common Stock at a 1:1 ratio, and Series A‑1 Preferred Stock converted into Class B at a 1:2.418 ratio. Each Class B share was then reclassified into one share of Common Stock.

Does this Alamar Biosciences (ALMR) Form 4 show any insider share sales?

The Form 4 does not report any open‑market purchases or sales. Instead, it details equity awards, automatic conversions of preferred and Class B shares into Common Stock, and administrative option reclassifications, all without a stated market sale of shares by Shiping Chen.